Noxopharm (ASX:NOX) ROE % Adjusted to Book Value : -19.77% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Noxopharm ROE % Adjusted to Book Value?

Noxopharm's ROE % for the quarter that ended in Dec. 2023 was -63.85%. Noxopharm's PB Ratio for the quarter that ended in Dec. 2023 was 3.23. Noxopharm's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -19.77%.

Noxopharm ROE % Adjusted to Book Value Historical Data

The historical data trend for Noxopharm's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm ROE % Adjusted to Book Value Chart

Noxopharm Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-1.51

-7.63

-24.48

-65.27

Noxopharm Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial										-13.68	-29.68	-22.33	-99.77	-19.77

Competitive Comparison of Noxopharm's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Noxopharm's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Noxopharm's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Noxopharm's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Noxopharm's ROE % Adjusted to Book Value falls into.

Noxopharm ROE % Adjusted to Book Value Calculation

Noxopharm's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-90.72%	/	1.39
	=	-65.27%

Noxopharm's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-63.85%	/	3.23
	=	-19.77%

Noxopharm ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Noxopharm's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Noxopharm (ASX:NOX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

NOXOF:USA

Address

60 Linksley Ave, Glenhaven, NSW, AUS, 2156

Website

https://www.noxopharm.com

Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

Noxopharm (ASX:NOX) Headlines

No Headlines